[Anticoagulants and thrombocyte aggregation inhibitors in the treatment of heart infarct. A survey].
The treatment of causes and complications of myocardial infarction is complicated by variable response to anticoagulants and inhibitors of platelet aggregation. No generally accepted principle for treatment of myocardial infarction is available at present. Following a literature review and after our own experience we suggest an immediate treatment of acute myocardial infarction with heparin and a switch to oral anticoagulants after heparin treatment of the acute phase. Three to four weeks after the acute myocardial infarction invasive diagnostic procedure should be performed. The result will lead to a decision about possibly extended therapy with oral anticoagulants. Left ventricular aneurysma e.g. would lead to prolonged coumarin-therapy. If no oral anticoagulants are necessary long term treatment with sulfinpyrazone or Aspirin plus dipyridamole should be initiated.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D003374:Coumarins / Q000627:therapeutic use; D004617:Embolism / Q000188:drug therapy; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010974:Platelet Aggregation / Q000187:drug effects*; D013927:Thrombosis / Q000188:drug therapy
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D003374:Coumarins; D006493:Heparin
Antikoagulantien und Thrombozyten--Aggregationshemmer in der Behandlung des Herzinfarkts. Ein Uberblick.